.svg "Veratrak"){kind=logo}
In an era of increasing environmental consciousness, the pharmaceutical industry finds itself at a critical juncture. With the implementation of the EU's Corporate Sustainability Reporting Directive in January 2024, large pharmaceutical organisations are facing growing pressure to enhance their sustainability reporting practices.
Our latest white paper, "Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry," offers an in-depth exploration of this timely topic. The paper discusses the growing emphasis on addressing Scope 3 emissions and the trend towards more comprehensive reporting and adoption of science-based targets.
Here's a glimpse of what you'll discover in our comprehensive analysis:
- Key Sustainability Frameworks and Initiatives shaping the pharmaceutical sector's approach to sustainability
- Industry-Wide Challenges and complexities of Scope 3 emissions reporting
- Comprehensive analysis of Scope 3 emissions data from the top 25 pharmaceutical and biotech organisations.
- Industry Trends and Future Outlook
This white paper is an essential resource for pharmaceutical industry professionals, sustainability experts, and anyone interested in the intersection of healthcare and environmental responsibility.
Download now to gain valuable insights into the current state of Scope 3 emissions reporting in the pharma industry and the path forward towards a more sustainable future.